Dashboard
1
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate -186.94% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -27.33
2
Flat results in Dec 20
3
Risky -
4
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
EUR 151 Million ()
NA (Loss Making)
NA
0.00%
-0.71
-167.66%
2.96
Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - Jun 2025)
Net Profit:
-21 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-54.47%
0%
-54.47%
6 Months
-44.41%
0%
-44.41%
1 Year
-50.06%
0%
-50.06%
2 Years
-45.0%
0%
-45.0%
3 Years
-69.35%
0%
-69.35%
4 Years
-82.03%
0%
-82.03%
5 Years
0%
0%
0.0%
Nyxoah SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
41.75%
EBIT Growth (5y)
-186.94%
EBIT to Interest (avg)
-27.33
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.47
Sales to Capital Employed (avg)
1.08
Tax Ratio
4.97%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
12.99%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.37
EV to EBIT
-2.03
EV to EBITDA
-2.11
EV to Capital Employed
2.99
EV to Sales
30.66
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-147.37%
ROE (Latest)
-106.46%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
Bearish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot : Dec 2023
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 1 Schemes (0.46%)
Foreign Institutions
Held by 42 Foreign Institutions (12.17%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
1.30
0.80
62.50%
Operating Profit (PBDIT) excl Other Income
-19.10
-12.70
-50.39%
Interest
0.40
0.10
300.00%
Exceptional Items
0.20
0.00
Consolidate Net Profit
-20.60
-13.10
-57.25%
Operating Profit Margin (Excl OI)
-14,836.60%
-17,334.60%
249.80%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 62.50% vs -27.27% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -57.25% vs -2.34% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
4.50
4.30
4.65%
Operating Profit (PBDIT) excl Other Income
-57.10
-43.30
-31.87%
Interest
1.90
1.20
58.33%
Exceptional Items
-0.40
-0.10
-300.00%
Consolidate Net Profit
-59.20
-43.20
-37.04%
Operating Profit Margin (Excl OI)
-13,230.90%
-10,498.20%
-273.27%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 4.65% vs 38.71% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -37.04% vs -38.46% in Dec 2023
About Nyxoah SA 
Nyxoah SA
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






